Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
2,226 stopped studies mapped to Malignant Digestive System Neoplasm and descendants · 91% state a reason
Over the 2,226 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT04571710 | A Trial of SHR1258 in Patients With Biliary Tract Cancer | Phase 2 | withdrawn | Oct 1, 2020 | Jiangsu HengRui Medicine Co., Ltd. | The sponsor's R\&D strategy is adjusted. | Sponsor / business decision |
| NCT05619172 | A Study of Nanrilkefusp Alfa (SOT101) in Combination With Cetuximab to Evaluate the… | Phase 2 | terminated | Nov 16, 2022 | SOTIO Biotech AG | Due to lack of efficacy shown at the time of the interim analysis. | Efficacy / futility |
| NCT06299163 | NM32-2668 in Adult Patients With Selected Advanced Solid Tumors | Phase 1 | terminated | Mar 7, 2024 | Numab Therapeutics AG | Business decision | Sponsor / business decision |
| NCT03547999 | A Trial of Perioperative CV301 Vaccination in Combination With Nivolumab and Systemic… | Phase 2 | terminated | Jun 6, 2018 | Patrick Boland | Drugs Unavailable | Other (stated, no rule matched) |
| NCT07043348 | Streamlining Radioembolization for Intrahepatic Cholangiocarcinoma(ISTAR-04) | — | terminated | Jun 29, 2025 | Seoul National University Hospital | This study was merged with NCT07043387. Thus, this study was terminated. | Other (stated, no rule matched) |
| NCT05834543 | Clinical Trial to Evaluate the Safety and Effectiveness of TQB2618 Injection Combined… | Phase 1 / Phase 2 | terminated | Apr 28, 2023 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | This study was closed due to business reasons. Closure was not prompted by any safety or efficacy… | Safety / toxicity |
| NCT04116320 | Focused Ultrasound Ablation and PD-1 Antibody Blockade in Advanced Solid Tumors(AM-003) | Phase 1 | terminated | Oct 4, 2019 | Craig L Slingluff, Jr | Unable to enroll enough patients to complete targeted enrollment in a reasonable time. | Enrollment / accrual |
| NCT04577963 | A Study of Fruquintinib in Combination With Tislelizumab in Advanced Solid Tumors | Phase 1 / Phase 2 | terminated | Oct 8, 2020 | Hutchmed | At the time of study termination, both fruquintinib and tislelizumab are commercially available in… | Other (stated, no rule matched) |
| NCT04561453 | Feasibility Study of Multi-Platform Profiling of Resected Biliary Tract Cancer | — | terminated | Sep 23, 2020 | University of Washington | Study terminated due to end of funding | Funding |
| NCT04992507 | Impact of Total Intravenous Anesthesia Following Cancer Surgery, TIVACS Study | Phase 2 | terminated | Aug 5, 2021 | Ohio State University Comprehensive Cancer Center | Principal investigator departed sponsoring organization | Investigator |
| NCT05563272 | 89Zr-girentuximab for PET Imaging of CAIX Positive Solid Tumors(STARBURST) | Phase 2 | terminated | Oct 3, 2022 | Telix Pharmaceuticals (Innovations) Pty Ltd | Indication scouting for TLX250-CDx will continue in theranostic studies, with a therapeutic… | Other (stated, no rule matched) |
| NCT01726309 | Single Nucleotide Polymorphism(SNP)Study. ICORG 08-40, V4 | — | terminated | Nov 14, 2012 | Cancer Trials Ireland | As per the HRBs new funding model, HRBs investment will not support costs associated with routine… | Funding |
| NCT02050737 | Plasma Biomarkers C-RAC, ICORG 12-27, V1 | — | terminated | Jan 31, 2014 | Cancer Trials Ireland | As per the HRBs new funding model, HRBs investment will not support costs associated with routine… | Funding |
| NCT05010850 | SafeHeal Colovac Colorectal Anastomosis Protection Device Evaluation (SAFE-2) Pivotal…(SAFE-2) | N/A | terminated | Aug 18, 2021 | SafeHeal Inc | Voluntary and temporary suspension of enrollment. | Enrollment / accrual |
| NCT04520906 | To Evaluate the Safety and Efficacy of Microwave Ablation Therapy in Patients With… | N/A | terminated | Aug 20, 2020 | Suzhou Hengruihongyuan Medical Technology Co. LTD | Obtaining medical device market approval through the predicate device comparison route. | Other (stated, no rule matched) |
| NCT04786600 | A Phase II Randomized Therapeutic Optimization Trial for Subjects With Refractory… | Phase 2 | terminated | Mar 8, 2021 | University of Florida | slow accrual | Enrollment / accrual |
| NCT05330429 | Study of Magrolimab Given Together With FOLFIRI/Bevacizumab (BEV) in Participants With…(ELEVATE CRC) | Phase 2 | terminated | Apr 15, 2022 | Gilead Sciences | Sponsor decision to terminate study | Sponsor / business decision |
| NCT05573035 | A Study to Investigate LYL845 in Adults With Solid Tumors | Phase 1 | terminated | Oct 10, 2022 | Lyell Immunopharma, Inc. | Pipeline Reprioritization | Other (stated, no rule matched) |
| NCT06572189 | The Safety and Efficacy of CD-801 in Patients With Advanced Intrahepatic… | Early Phase 1 | withdrawn | Aug 27, 2024 | Shanghai Changzheng Hospital | Based on the results of another intravenous injection therapy CD-801 for the treatment of… | Other (stated, no rule matched) |
| NCT05432193 | FAPi Radioligand OpeN-Label, Phase 1 Study to Evaluate Safety, Tolerability and DosImetry… | Phase 1 | terminated | Jun 27, 2022 | POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company | Business decision | Sponsor / business decision |
| NCT06370663 | First-line Treatment for Unresectable Locally Advanced Distal Cholangiocarcinoma… | Phase 2 | terminated | Apr 17, 2024 | Shandong Cancer Hospital and Institute | Study was terminated due to unacceptable treatment-related toxicity that raised safety concerns and… | Safety / toxicity |
| NCT06707896 | TCR1020-CD8 T Cells in KRAS-mutated Cancers | Phase 1 | withdrawn | Nov 27, 2024 | University of Pennsylvania | Administrative decision | Other (stated, no rule matched) |
| NCT05630937 | Study on Safety and Efficacy of NMS-01940153E in Adult Patients With Unresectable… | Phase 1 / Phase 2 | terminated | Nov 30, 2022 | Nerviano Medical Sciences | In the Phase II part of the study, among the participants evaluable for efficacy, no objective… | Efficacy / futility |
| NCT06728657 | Preoperative HFRT Verses PULSAR for Locally Advanced GEJ or Proximal Gastric…(TORCH-G) | Phase 2 | suspended | Dec 11, 2024 | Fudan University | Difficult in recruiting participants | Enrollment / accrual |
| NCT05461794 | Study To Investigate the Efficacy and Safety of Sitravatinib in Combination With… | Phase 2 | terminated | Jul 18, 2022 | BeiGene | Due to modification of company strategy. | Sponsor / business decision |
| NCT05342350 | International Study of High-Risk Patients for Hepatocellular Carcinoma Using Liquid Biopsy(STOP-HCC) | — | terminated | Apr 22, 2022 | Johns Hopkins University | PI moving on from current institution | Other (stated, no rule matched) |
| NCT05841706 | Red Blood Cell Transfusion Thresholds for Improved Quality of Life for Patients… | Early Phase 1 | terminated | May 3, 2023 | Jonsson Comprehensive Cancer Center | slow accrual | Enrollment / accrual |
| NCT04727151 | TAC T-cells for the Treatment of HER2-positive Solid Tumors(TACTIC-2) | Phase 1 / Phase 2 | terminated | Jan 27, 2021 | Triumvira Immunologics, Inc. | Study terminated by Sponsor for commercial reasons | Other (stated, no rule matched) |
| NCT05067842 | Circulating Tumor DNA (ctDNA) in Locally Advanced Esophageal and Gastroesophageal (GE)…(TRACT DNA) | — | withdrawn | Oct 5, 2021 | Medical College of Wisconsin | Low accrual and PI leaving institution | Enrollment / accrual |
| NCT04964297 | Evaluation of Ability to Detect Bowel Gas During Laparoscopic Right Colectomy With… | N/A | terminated | Jul 16, 2021 | Weill Medical College of Cornell University | Need for device upgrade. | Other (stated, no rule matched) |
| NCT05657418 | A Clinical Study to Evaluate the Safety and Tolerability of JS107 in Advanced Pancreatic… | Phase 1 | terminated | Dec 20, 2022 | Shanghai Junshi Bioscience Co., Ltd. | Company research and development strategy adjustment | Sponsor / business decision |
| NCT06592664 | Certepetide Phase 1b/2a Continuous Infusion Trial in mPDAC(FORTIFIDE) | Phase 1 / Phase 2 | withdrawn | Sep 19, 2024 | Lisata Therapeutics, Inc. | Management Decision | Other (stated, no rule matched) |
| NCT04148378 | A Pilot Study to Explore the Role of Gut Flora in Colorectal Cancer | — | withdrawn | Nov 1, 2019 | ProgenaBiome | Company shifted focus | Sponsor / business decision |
| NCT05603572 | KAT-101 in Subjects With Hepatocellular Carcinoma (HCC) | Phase 1 / Phase 2 | suspended | Nov 2, 2022 | Primocure Pharma | Enrollment paused | Enrollment / accrual |
| NCT06494046 | Defining Musical Toxicity and Its Effect on Patient Well-being | — | withdrawn | Jul 10, 2024 | Mayo Clinic | Resident working with study left institution | Other (stated, no rule matched) |
| NCT00529113 | Study With Gemcitabine and RTA 402 for Patients With Unresectable Pancreatic Cancer | Phase 1 | terminated | Sep 14, 2007 | Biogen | To pursue other indications | Other (stated, no rule matched) |
| NCT04152018 | Study of PF-06940434 in Patients With Advanced or Metastatic Solid Tumors. | Phase 1 | terminated | Nov 5, 2019 | Pfizer | Study termination was based on strategic considerations and not due to specific safety reasons or a… | Safety / toxicity |
| NCT05287347 | Panc CA Risk Model & Biomarker Testing In High-Risk Cohort | — | withdrawn | Mar 18, 2022 | Beth Israel Deaconess Medical Center | Lack of funding | Funding |
| NCT05480891 | Transnasal Esophagoscopy (TNE) Esophageal Cancer Screening | — | terminated | Jul 29, 2022 | University of Illinois at Chicago | Transnasal Esophagoscopy (TNE) scope is no longer manufactured so the study is unable to be… | Drug supply |
| NCT04442126 | A Study of NM21-1480 in Adult Patients With Advanced Solid Tumors | Phase 1 / Phase 2 | terminated | Jun 22, 2020 | Numab Therapeutics AG | A business decision was made to discontinue further enrollment. There were no safety concerns that… | Safety / toxicity |
| NCT06361758 | Second-line Treatment With CAdonilimab and LEnvatinib for Unresectable HCC | Phase 2 | withdrawn | Apr 12, 2024 | Shanghai Zhongshan Hospital | The PI has initiated a global multicenter Phase II clinical trial in the same direction, conducted… | Other (stated, no rule matched) |
| NCT06077487 | Ketamine-assisted Therapy for Advanced GI Cancer | Phase 4 | terminated | Oct 11, 2023 | Brian Anderson, MD | Slow Accrual | Enrollment / accrual |
| NCT06895577 | Neoadjuvant Chemoradiotherapy Plus Sintilimab for MSS, Locally Advanced Rectal Cancer- | Phase 2 | withdrawn | Mar 26, 2025 | Sun Yat-sen University | Due to errors in the previously submitted modification, we request to withdraw it and will submit a… | Other (stated, no rule matched) |
| NCT04479436 | A Study to Evaluate U3-1402 in Subjects With Advanced or Metastatic Colorectal Cancer | Phase 2 | terminated | Jul 21, 2020 | Daiichi Sankyo | Study was terminated early given the Interim Analysis for Part 1 (signal finding) did not meet… | Efficacy / futility |
| NCT04856787 | A Clinical Studyf of SHR-1701 or Placebo in Combination With BP102 and XELOX in the… | Phase 2 / Phase 3 | terminated | Apr 23, 2021 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Adjustment of the Company's R\&D Strategy | Sponsor / business decision |
| NCT02467582 | Adjuvant Aspirin Treatment for Colon Cancer Patients | Phase 3 | terminated | Jun 10, 2015 | Swiss Cancer Institute | Board decision in 2020 due to lack of financial funding. | Funding |
| NCT03534141 | Mild Hypothermia and Acute Kidney Injury in Liver Transplantation(MHALT) | N/A | terminated | May 23, 2018 | University of California, San Francisco | Terminated 9/24/23 at 85% target enrollment due to slow accrual of subjects. The decline in… | Enrollment / accrual |
| NCT03879811 | Determining the Effects of Temozolomide Followed by Nivolumab in Patients With Colorectal… | Phase 2 | withdrawn | Mar 19, 2019 | Memorial Sloan Kettering Cancer Center | No accrual | Enrollment / accrual |
| NCT04965311 | Endoscopic Botulinum Toxin Injection in the Prevention of Postoperative Pancreatic… | Phase 2 | terminated | Jul 16, 2021 | OHSU Knight Cancer Institute | low enrollment | Enrollment / accrual |
| NCT02047500 | Phase I TH-302 Plus Gemcitabine Plus Nab-Paclitaxel in Pancreatic Cancer | Phase 1 | terminated | Jan 28, 2014 | ImmunoGenesis | The trial has been terminated earlier following the company decision to discontinue the clinical… | Sponsor / business decision |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Jul 24, 2025source: clinicaltrials